These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27235615)

  • 1. Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.
    Berkseth KE; Thirumalai A; Amory JK
    Med Clin North Am; 2016 Jul; 100(4):791-805. PubMed ID: 27235615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction].
    Kamalov AA; Takhirzade AM
    Urologiia; 2018 Jul; (3):70-77. PubMed ID: 30035422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
    Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
    Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone therapy in erectile dysfunction and hypogonadism.
    Shabsigh R
    J Sex Med; 2005 Nov; 2(6):785-92. PubMed ID: 16422803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction].
    Kamalov AA; Takhirzade AM
    Urologiia; 2017 Dec; (6):160-163. PubMed ID: 29376615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Erectile disfunction and benign prostatic hyperplasia - causal relation or coincidence?].
    Gasser T
    Ther Umsch; 2010 Mar; 67(3):145-7. PubMed ID: 20235043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving role of testosterone in the treatment of erectile dysfunction.
    Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J
    Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
    Traish AM
    Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical therapy for benign prostatic hyperplasia: a review.
    Van Asseldonk B; Barkin J; Elterman DS
    Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.
    La Vignera S; Aversa A; Cannarella R; Condorelli RA; Duca Y; Russo GI; Calogero AE
    Expert Opin Pharmacother; 2021 Feb; 22(2):179-189. PubMed ID: 32902360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future options for combination therapy in the management of erectile dysfunction in older men.
    Sommer F; Engelmann U
    Drugs Aging; 2004; 21(9):555-64. PubMed ID: 15260511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology for common urologic diseases: 2011 review for the primary care physician.
    Liu XS; Folia C; Gomella LG
    Can J Urol; 2011 Apr; 18 Suppl():24-38. PubMed ID: 21501548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.
    Shigehara K; Sugimoto K; Konaka H; Iijima M; Fukushima M; Maeda Y; Mizokami A; Koh E; Origasa H; Iwamoto T; Namiki M
    Aging Male; 2011 Mar; 14(1):53-8. PubMed ID: 21171937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Men's health. Summary and table.
    Palmer KJ; Wiseman L; Poole R
    Drugs R D; 1999 Dec; 2(6):401-11. PubMed ID: 10763452
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy].
    Volkov AA; Petrichko MI; Budnik NV; Dukhin AR
    Urologiia; 2013; (2):56, 58-9. PubMed ID: 23789365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between hypogonadism and erectile dysfunction.
    Hwang TI; Lin YC
    Int J Impot Res; 2008; 20(3):231-5. PubMed ID: 18305486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile dysfunction and hypogonadism (low testosterone).
    Barkin J
    Can J Urol; 2011 Apr; 18 Suppl():2-7. PubMed ID: 21501544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism].
    Mazo EB; Gamidov SI; Sotnikova EM
    Ter Arkh; 2008; 80(12):59-63. PubMed ID: 19227909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.